Paul Jeng
Stock Analyst at Guggenheim
(0.56)
# 3,658
Out of 4,411 analysts
25
Total ratings
31.8%
Success rate
-9.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Paul Jeng
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRBP Corbus Pharmaceuticals Holdings | Maintained: Buy | $45 | $7.88 | +471.07% | 2 | Jun 2, 2026 | |
| IDYA IDEAYA Biosciences | Maintained: Buy | $54 | $30.57 | +76.64% | 7 | Jun 2, 2026 | |
| IMTX Immatics | Maintained: Buy | $19 | $9.09 | +109.02% | 5 | May 12, 2026 | |
| CHRS Coherus Oncology | Initiated Coverage: Buy | $12 | $1.38 | +769.57% | 1 | May 11, 2026 | |
| CNTX Context Therapeutics | Maintained: Buy | $5 | $0.6503 | +668.88% | 4 | May 6, 2026 | |
| ADAG Adagene | Maintained: Buy | $10 | $3.53 | +183.29% | 4 | Apr 6, 2026 | |
| IMCR Immunocore Holdings | Initiated Coverage: Hold | n/a | $28.17 | - | 1 | Sep 17, 2025 | |
| TARA Protara Therapeutics | Initiated Coverage: Buy | $50 | $3.81 | n/a | 1 | Jul 29, 2020 |
Corbus Pharmaceuticals Holdings
Jun 2, 2026
Maintained: Buy
Price Target: $45
Current: $7.88
Upside: +471.07%
IDEAYA Biosciences
Jun 2, 2026
Maintained: Buy
Price Target: $54
Current: $30.57
Upside: +76.64%
Immatics
May 12, 2026
Maintained: Buy
Price Target: $19
Current: $9.09
Upside: +109.02%
Coherus Oncology
May 11, 2026
Initiated Coverage: Buy
Price Target: $12
Current: $1.38
Upside: +769.57%
Context Therapeutics
May 6, 2026
Maintained: Buy
Price Target: $5
Current: $0.6503
Upside: +668.88%
Adagene
Apr 6, 2026
Maintained: Buy
Price Target: $10
Current: $3.53
Upside: +183.29%
Immunocore Holdings
Sep 17, 2025
Initiated Coverage: Hold
Price Target: n/a
Current: $28.17
Upside: -
Protara Therapeutics
Jul 29, 2020
Initiated Coverage: Buy
Price Target: $50
Current: $3.81
Upside: n/a